Chapter 1. LIVE ATTENUATED VACCINES MARKET– Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. LIVE ATTENUATED VACCINES MARKET– Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-131 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. LIVE ATTENUATED VACCINES MARKET– Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. LIVE ATTENUATED VACCINES MARKET- Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. LIVE ATTENUATED VACCINES MARKET- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. LIVE ATTENUATED VACCINES MARKET– By Product Type
6.1. Viral
6.2. Bacterial
Chapter 7. LIVE ATTENUATED VACCINES MARKET– By Development
7.1. Tissue Culture
7.2. Embryonated Eggs
7.3. Live Animals
Chapter 8. LIVE ATTENUATED VACCINES MARKET– By Indication
8.1. Measles
8.2. Rotavirus
8.3. Oral Polio
8.4. Tuberculosis
8.5. Yellow Fever
8.6. Others
Chapter 9. LIVE ATTENUATED VACCINES MARKET– By Mode of Administration
9.1. Oral
9.2. Injectable
9.3. Others
Chapter 10. LIVE ATTENUATED VACCINES MARKET– By Distribution Channel
10.1. Online Pharmacies
10.2. Retail Pharmacies
10.3. Hospital Pharmacies
Chapter 11. LIVE ATTENUATED VACCINES MARKET– By End-User
11.1. Specialty Clinics
11.2. Hospitals
11.3. Homecare
11.4. Others
Chapter 12. LIVE ATTENUATED VACCINES MARKET– By Region
12.1. North America
12.2. Europe
12.3. The Asia Pacific
12.4. Latin America
12.5. Middle-East and Africa
Chapter 13. LIVE ATTENUATED VACCINES MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)
13.1. Company 1
13.2. Company 2
13.3. Company 3
13.4. Company 4
13.5. Company 5
13.6. Company 6
13.7. Company 7
13.8. Company 8
13.9. Company 9
13.10. Company 10
2850
5250
4500
1800